Cancer Diagnostics Market– Our new study reveals trends, R&D progress, and predicted revenues over the next decade

Growing Demand for Non-Invasive Cancer Diagnosis
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market. For instance, VolitionRx Limited, released its Nu.Q colorectal cancer triage test in Europe. Similarly, OncoCyte Corporation, developer of the new DetermaIO, a biomarker of triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) neoadjuvant control point inhibitor response, is expected to be launched in the US by 2H2021. All these factors are anticipated to offer lucrative growth opportunities for the cancer diagnostics market players over the forecast period.

North America Currently Dominates the Global Cancer Diagnostics Market
Based on regions, the global cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to analysis, North America cancer diagnostics accounted for majority of the market share and is projected to witness significant growth over the forecast period from 2021 to 2031. The growth is attributed to rising cancer burden which is influenced by many factors, such as aging populations and shift in lifestyle patterns. Patients are encouraged to use healthcare facilities by enhancing compensation. Various cancer prevention programs are organized by government agencies (such as the Colorectal Cancer Control Program) to increase the cancer screening among men & women aged 50 years and above.

How are prominent players reinforcing their position across the global business?
Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies. See where the expected gains will be. View this assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of leading companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and outlook.

Discover how to stay ahead
Our 590+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Cancer Diagnostics Market. See how to exploit the opportunities.

Cancer Diagnostics Market Segmentation

Test Type

• Tumor Biomarkers Tests
• PSA Tests
• CTC Tests
• AFP Tests
• CA-19 Tests
• HER2 Tests
• BRCA Tests
• ALK Tests
• CEA Tests
• EGFR Mutation Tests
• KRAS Mutation Tests
• Others

• Imaging
• Ultrasound
• Mammography
• MRI Scan
• PET Scan
• CT Scan
• SPECT & Others

• Biopsy
• Needle Biopsy
• Endoscopic Biopsy
• Bone Marrow Biopsy
• Others

• Liquid Biopsy
• Immunohistochemistry
• In Situ Hybridization

Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Blood Cancer
• Prostate Cancer
• Ovarian Cancer
• Stomach Cancer
• Liver Cancer
• Others

End-User
• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Other End-Users

By Region

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

 Japan

Asia Pacific Excluding Japan

  • China
  • Australia
  • India
  • Singapore
  • South Korea
  • Thailand
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa